Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary.
07.06.2024 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with .
Monashee Investment Management LLC lessened its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 34.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,459,854 shares of the company’s stock after selling 1,844,358 shares during the period. Gossamer Bio […]
This article highlights upcoming events in the financial world, including quarterly earnings reports, IPOs, investor events, and market volatility updates.